GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent
暂无分享,去创建一个
A. Howard | Daphne Szeto | Gail Forrest | D. Tatosian | S. Colletti | J. Di Salvo | A. Weinglass | H. Chobanian | Michele J Pachanski | J. Mane | C. Plummer | Sarah Souza | Brande S Thomas-Fowlkes | B. Cheewatrakoolpong | M. Trujillo | Corin O. Miller | Yue Feng | Melissa E Kirkland | Daniel T Kosinski | X. Li | Aimie Ogawa | J. Xue | Michelle Bunzel | Michael W. Miller
[1] M. Erion,et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy , 2017, Science.
[2] A. Howard,et al. GPR40 reduces food intake and body weight through GLP-1. , 2017, American journal of physiology. Endocrinology and metabolism.
[3] A. Howard,et al. Design and Synthesis of Novel, Selective GPR40 AgoPAMs. , 2017, ACS medicinal chemistry letters.
[4] Nicholas J Agard,et al. Synthesis of the GPR40 Partial Agonist MK-8666 through a Kinetically Controlled Dynamic Enzymatic Ketone Reduction. , 2016, Organic letters.
[5] M. Erion,et al. Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus. , 2016, American journal of physiology. Endocrinology and metabolism.
[6] T. Schwartz,et al. GPR40 (FFAR1) – Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo , 2014, Molecular metabolism.
[7] K. Takeuchi,et al. A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 , 2013, PloS one.
[8] C. Burant. Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes , 2013, Diabetes Care.
[9] D. Drucker,et al. Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.
[10] S. Wong,et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1 , 2013, Molecular and Cellular Endocrinology.
[11] M. Jensen,et al. The Role of Voltage-Gated Potassium Channels Kv2.1 and Kv2.2 in the Regulation of Insulin and Somatostatin Release from Pancreatic Islets , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[12] Sean P. Brown,et al. Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor , 2012, Molecular Pharmacology.
[13] Sean P. Brown,et al. A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents , 2012, PloS one.
[14] J. Holst,et al. Regulation of glucagon secretion by incretins , 2011, Diabetes, obesity & metabolism.
[15] Masahiro Ito,et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. , 2010, ACS medicinal chemistry letters.
[16] Michael E. Lassman,et al. Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.
[17] H. Davis,et al. Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet–Induced Metabolic Disease , 2008, Diabetes.
[18] Yun-ping Zhou,et al. Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice , 2008, Diabetes.
[19] J. Fornwald,et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules , 2006, British journal of pharmacology.
[20] S. Hinuma,et al. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.
[21] S. Burgess,et al. Glucose production, gluconeogenesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic resonance analysis of a single glucose derivative. , 2004, Analytical biochemistry.
[22] D. Drucker,et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[23] G. Grodsky,et al. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. , 1974, The Journal of clinical investigation.
[24] P. Lacy,et al. Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas , 1967, Diabetes.
[25] Michael E. Lassman,et al. Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test. , 2016, Clinical chemistry.
[26] Zhiguang Guo,et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. , 2013, Metabolism: clinical and experimental.
[27] M. Erion,et al. Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents , 2012, Biopolymers.